Previous studies have supported that activation of NF-κB by Epstein-Barr virus (EBV) infection largely participates in resistance of BL cell lines to TRAIL-induced apoptosis, and consequently, application of NF-κB inhibitors may be valuable for defeating BL cells resistance to TRAIL (Figure 3) (36). The gene discussed is NFKB1; the disease is Burkitt lymphoma.